Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 5/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031354 | 0.83 | MAPK14 (0.39) | MAPK14BRAFMAPK11 | |
| SCHEMBL4035041 | 0.76 | BRAF (0.45) | MAPK14BRAF | |
| SCHEMBL4032953 | 0.75 | BRAF (0.43) | MAPK14BRAF | |
| SCHEMBL13848860 | 0.74 | BRAF (0.43) | MAPK14BRAF | |
| SCHEMBL4034585 | 0.70 | BRAF (0.43) | MAPK14BRAF | |
| SCHEMBL4033769 | 0.70 | MAPK14 (0.41) | MAPK14ALDH1A1MAPK1MAPK11 | |
| SCHEMBL4036265 | 0.69 | BRAF (0.42) | MAPK14BRAF | |
| SCHEMBL4037019 | 0.69 | BRAF (0.42) | MAPK14BRAF | |
| SCHEMBL4031171 | 0.68 | BRAF (0.46) | MAPK14BRAF | |
| SCHEMBL4015103 | 0.68 | MAPK14 (0.38) | MAPK14ALDH1A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4850824-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |